What changed: Low-grade serous ovarian cancer

Cancer page →

Every dated change on the records linked to Low-grade serous ovarian cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Approval1Milestone3This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordLow-grade serous ovarian cancer
Facts on this page last checked
When this page itself was last checked or edited.

2025 · 2

2025ApprovalAvutometinib + defactinib
Avutometinib + defactinib approved in US
KRAS-mutated recurrent low-grade serous ovarian cancer after prior systemic therapy (accelerated)
2025MilestoneAvutometinib + defactinib
Avutometinib plus defactinib approved for KRAS-mutant disease
A milestone in how this cancer is treated.

2022 · 1

2022MilestoneTrametinib
GOG 281: trametinib doubles progression-free survival
A milestone in how this cancer is treated.

2004 · 1

2004MilestoneLow-grade serous ovarian cancer
Two-tier grading separates low-grade from high-grade serous cancer (MD Anderson)
A milestone in how this cancer is treated.